期刊文献+

外周血单核细胞和中性粒细胞计数预测转移性非小细胞肺癌患者对免疫检查点抑制剂反应的临床价值 被引量:3

Clinical value of peripheral monocyte and neutrophil count in predicting the response of patients with metastatic non-small cell lung cancer to immunosuppressive checkpoint inhibitors
原文传递
导出
摘要 目的探讨外周血单核细胞和中性粒细胞计数预测转移性非小细胞肺癌(mNSCLC)患者对免疫检查点抑制剂(ICI)治疗反应的临床价值。方法回顾性研究2017年1月至2019年3月在海南省儋州市人民医院接受纳武利尤单抗或帕博利珠单抗治疗的34例成年mNSCLC患者资料,记录并分析患者的人口学特征、临床资料、开始治疗前2周内和ICI治疗后2周血液学检查结果与预后的相关性。结果对ICI治疗有反应患者的基线中位单核细胞计数和中性粒细胞计数均低于无反应患者[(0.52±0.09)×10^(9)/L比(0.60±0.12)×10^(9)/L,(4.27±0.87)×10^(9)/L比(5.39±1.02)×10^(9)/L],差异均有统计学意义(t值分别为-2.572、-2.727,均P<0.05)。对ICI治疗有反应患者的单核细胞计数与反应时间呈负相关(r=-0.507,P<0.05)。单核细胞计数>0.70×10^(9)/L患者的中位反应时间短于单核细胞计数≤0.70×10^(9)/L的患者(8周比12周),差异有统计学意义(χ^(2)=4.162,P=0.041)。单核细胞计数与反应持续时间、无进展生存及总生存之间均无相关性(r值分别为-0.214、0.182、0.232,均P>0.05)。对ICI治疗有反应患者的中性粒细胞计数降低22%,高于无反应患者的2%,差异有统计学意义(P<0.05)。首次给药后中性粒细胞计数截断值为4.2×10^(9)/L,中性粒细胞计数≤4.2×10^(9)/L患者的反应率高于>4.2×10^(9)/L患者[86.7%(13/15)比36.8%(7/19)],差异有统计学意义(χ^(2)=6.657,P<0.05)。结论外周血单核细胞和中性粒细胞计数对mNSCLC患者ICI治疗反应具有一定预测价值。 Objective To investigate the clinical value of peripheral monocyte and neutrophil count in predicting the response of patients with metastatic non-small cell lung cancer(mNSCLC)to immunosuppressive checkpoint inhibitors(ICI).Methods The clinical data of 34 adult mNSCLC patients who received nafulizumab or pabolizumab in Danzhou People's Hospital of Hainan Province from January 2017 to March 2019 were retrospectively analyzed.The correlation of the demographic characteristics,clinical data,hematological examination results in the first two weeks before the treatment and two weeks after ICI treatment with prognosis was recorded and observed.Results The baseline mean monocyte count[(0.52±0.09)×10^(9)/L vs.(0.60±0.12)×10^(9)/L]and neutrophil count[(4.27±0.87)×10^(9)/L vs.(5.39±1.02)×10^(9)/L]of patients with ICI reaction were lower than those of patients without ICI reaction,and the differences were statistically different(t=-2.572,-2.727,all P<0.05).However,there was a negative correlation between the monocyte count of the patients who responded to ICI and the reaction time(r=-0.507,P<0.05).The median reaction time in patients with monocyte count>0.70×10^(9)/L was shorter than that in patients with monocyte count≤0.70×10^(9)/L(8 weeks vs.12 weeks,χ^(2)=4.162,P=0.041).There was no correlation between monocyte count and time of reaction duration,progression of free survival(PFS)and overall survival(OS)(r=-0.214,0.182,0.232,all P>0.05).The decrease rate of neutrophil count in response group was higher than that in non-response group(22%vs.2%,P<0.05).After the first administration,cutoff value of neutrophil count was 4.2×10^(9)/L;the response rate of patients with neutrophil count≤4.2×10^(9)/L was higher than that of patients with neutrophil count>4.2×10^(9)/L[86.7%(13/15)vs.36.8%(7/19),χ^(2)=6.657,P<0.05].Conclusion Peripheral blood monocyte and neutrophil count can predict the response to ICI therapy in patients with mNSCLC.
作者 郑文宏 符丽娟 郑小妹 谢文蕊 邓程伟 吴大平 华海琴 Zheng Wenhong;Fu Lijuan;Zheng Xiaomei;Xie Wenrui;Deng Chengwei;Wu Daping;Hua Haiqin(Department of Internal Medicine-Oncology,Danzhou People's Hospital of Hainan Province,Danzhou 571700,China;Department of Traditional Chinese Medicine,Danzhou People's Hospital of Hainan Province,Danzhou 571700,China)
出处 《肿瘤研究与临床》 CAS 2021年第1期24-27,共4页 Cancer Research and Clinic
关键词 非小细胞肺 单核细胞 中性粒细胞 免疫检查点抑制剂 Carcinoma,non-small-cell lung Monocytes Neutrophils Immune checkpoint inhibitors
作者简介 通信作者:郑文宏,Email:214475418@qq.com。
  • 相关文献

参考文献4

二级参考文献16

  • 1Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas[J]. J Clin Invest, 2012, 122(3) :787-795.
  • 2Gupta It, Dai L, Datta G, et al. Inhibition of lipopolysac-charide- induced inflammatory responses by an apolipoprotein A1 mimetic peptide[ J ]. Circ Res, 2005, 97 (3) :236-243.
  • 3Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophagc plasticity in experimental atherosclerosis [ J ]. PLoS One, 2010,5 ( 1 ) :e8852.
  • 4Lawrence T, Natoli G. Transcriptional regulation of macro-phage polarization: enabling diversity with identity [ J ]. Nat Rev Immu-nol, 2011, 11(1l) : 750-761.
  • 5Hasegawa-Moriyama M, Kurimoto T, Nakama M, et al. Pemxisome proliferator-activated receptor-gamma agonist rosigfitazone attenu- ates inflammatory pain through the induction of heme oxygenase-1 in macrophages [ J ]. Pain,2013,154 (8) : 1402-1412.
  • 6Liu C, Li Y, Yu ], et al. Targeting the shift from bll to M2 mac- mphages in experimental autoimmune encephalomy-elitis mice trea- ted with fasudil[J]. PLoS One, 2013, 8(2) : e54841.
  • 7Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immuni- ty and fatty acid-induced insulin resistance [ J ]. J Clin Invest, 2006,116( 11 ) :3015-3025.
  • 8Coenen KR, Gruen ML, Lee-Young RS, et al. Impact of macro- phage Toll-like receptor 4 deficiency on macrophage infiltration into adipose tissue and the artery wall in mice[ J]. Diabetologia, 2009, 52(2) :318-328.
  • 9Orr JS, Puglisi MJ, Ellacott KL, et al. Toll-like receptor 4 defi- ciency promotes the alternative activation of adipose tissue macro- phages [J]. Diabetes, 2012, 61 (11): 2718-2727.
  • 10翟振丽,马维红,李全忠,申炜,阳跃忠.载脂蛋白A1诱导骨髓源性巨噬细胞向抗炎性M2型极化的作用[J].中国动脉硬化杂志,2013,21(10):865-870. 被引量:3

共引文献14

同被引文献15

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部